Fully-Optimized Lentiviral Vector Vaccine Platform
MOST EFFICIENT & SAFEST PLATFORM by DESIGN: 20+ years of research and development on lentivirus converge in our vaccine platform, thoroughly optimized to deliver the safest and most efficient lentiviral vector vaccines.
SAFETY DEMONSTRATED THROUGH QUANTITATIVE & QUALITATIVE BIODISTRIBUTION STUDIES, CARCINOGENICITY AND ONE PHASE I/IIA STUDY
SPECTACULAR EFFICACY STUDY
An intense, broad & long-lasting T-cell Immune Response
- Endogenous Antigen Processing leading to sustained Presentation through the whole Dendritic Cell (DC) Life
- Physiological maturation of DC, no need for adjuvant
- Long-term T-cell immunity challenged in various animal models including through lethal challenges

Challenged against real pathogens
- HIV: Best protection ever described in a predictive macaque/SIVmac 251 model
- Malaria: Unique long-term sterile cellular immunity by a liver-stage vaccine
- Zika: Long-term sterilizing protection
- MDR Tuberculosis: unrivaled BCG boost
Back-to-back Comparisons with other vaccine candidates
- Zika vaccine vs Plasmid & RNA vaccines
- HIV vaccine vs Adeno Boost & VSV vaccines
The vaccine approach with a real chance against Cancer
- Therapeutic Melanoma Vaccine shows outstanding tumor clearance results
- Straight forward approach for virally-induced cancers